CION Ameerpet
Pancreatic Cancer · Questions People Ask Most · Reviewed by CION Oncologists
Is there a screening test for pancreatic cancer? — the honest answer, and what to do instead
For a healthy adult with no family pattern, the answer is no — and no major guideline recommends one. This page explains why, what a CA 19-9, an ultrasound or a whole-body scan genuinely tells you, who is offered surveillance instead, and the one symptom that should never wait for a screening programme.
- No test is recommended for well adults — not a blood marker, not an annual scan, not a health package.
- Screening and surveillance are different — a narrow high-risk group is offered a defined programme.
- CA 19-9 is not a screening test — it rises in benign disease and can be normal in cancer.
- Painless jaundice never waits — the one sign that means a same-week check, screening or not.
17+
Cancer Specialists
on Panel
on Panel
35+
Centres Across
Telangana & AP
Telangana & AP
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
Start here
The Short Answer, and Why It Sounds Unsatisfying
No. For an adult who feels well, has no symptoms, no strong family pattern and no known inherited gene change, there is no pancreatic cancer screening test that any major guideline recommends — NCCN included. Not a blood test, not an annual ultrasound, not a scan bundled into an executive health package. That is an uncomfortable thing to be told when you have come looking for reassurance, and it is the honest answer.
The word doing the work here is “screening.” Screening means testing well people who feel entirely fine, in the hope of catching a disease before it announces itself. That is a different job from investigating someone who already has jaundice, weight loss or a suspicious finding on a scan — that is diagnosis. The pancreas has good diagnostic tests. What it does not have is a test that earns its place as a screening test for the whole population.
Three things stand in the way. The gland sits deep in the abdomen, behind the stomach and in front of the spine, where a simple scan cannot see it clearly. No blood marker is specific enough to separate an early cancer from gallstone disease, pancreatitis or a bile duct that is simply blocked. And pancreatic cancer, while serious, is uncommon enough in the general population that testing everybody would produce far more false alarms than cancers found. A false alarm here is not harmless: it can mean repeat scans over months, a sedated endoscopic procedure, and a year of fear over something that was never cancer.
There is one genuine exception. A narrow group — people carrying particular inherited gene changes, and families in which several close relatives have had the disease — are offered regular testing, and for them it is worthwhile. That group and its criteria are set out in full in pancreatic cancer screening for people at high risk. For that group the correct word is surveillance, not screening, and the distinction matters more than it sounds. The complete pancreatic cancer guide covers the wider picture; this page stays on the tests themselves and what each one is actually for.
Did you know? The international consensus recommendations on pancreatic surveillance, produced by the international Cancer of the Pancreas Screening consortium and reflected in NCCN guidance, never define a screening test for the general population at all. What they define is an eligibility list — named inherited gene changes, and families with several affected close relatives — and then what surveillance for that small group should consist of: MRI with MRCP and endoscopic ultrasound, used in alternation at set intervals, in centres experienced in reading pancreatic images. CA 19-9 is deliberately not the entry test, because it rises in gallstone disease, in pancreatitis and in any blocked bile duct, and because a proportion of people never produce it at all owing to their Lewis blood-group type. The guidance is precise about who should be tested, and just as precise about who should not be.
The tests people buy
What a Health Package Actually Does for the Pancreas
Executive health checks and whole-body scans are marketed as cancer checks. Here is what each one genuinely is, and genuinely is not.
Tumour marker panel
A CA 19-9 taken in a health check
This marker was developed to follow a cancer that is already known about and to watch how it responds to treatment. It rises in gallstone disease, in pancreatitis and whenever the bile duct is blocked, and it can sit inside the normal range while a tumour is present. A single reading in a well person settles almost nothing, in either direction.
Abdominal ultrasound
The quick scan of the upper abdomen
Genuinely useful for gallstones and for showing a dilated bile duct, which is often the first clue that something is obstructing it. But the pancreas lies behind the stomach and behind bowel gas, and the tail of the gland is frequently not seen at all. A normal ultrasound does not exclude a pancreatic tumour.
Whole-body PET-CT
The scan most often asked for by name
PET-CT is a staging tool for a cancer that has already been diagnosed. Used on a well person it lights up inflammation as readily as tumour and turns up findings in the thyroid, lung or bowel that then have to be chased. It is coordinated with partner imaging centres, is not offered here as a check-up, and is not a screening test.
General abdominal CT
A routine scan, not a pancreatic one
A small pancreatic lesion is often visible only on a dedicated pancreatic-protocol contrast study, timed to catch the arterial and venous phases as contrast passes through the gland. A general abdominal CT done for another reason can miss what the correct protocol would have shown.
MRI with MRCP
Detailed, and reserved for a reason
MRI with MRCP is the workhorse of high-risk surveillance and of pancreatic cyst follow-up, because it shows the ducts well without radiation. It is used where there is a reason to look. As an annual check on a healthy person with no risk factors, it creates more questions than it answers.
Genetic risk testing
The one test that can change your plan
Where the family history warrants it, a gene panel with proper counselling before and after can identify the small group for whom surveillance genuinely is recommended. This is testing your risk rather than testing for a tumour — a different question, and the one worth asking. Counselling and testing are arranged in-house at CION.
Three different things
Screening, Surveillance and Testing a Symptom Are Not the Same
Most of the confusion about screening for pancreatic cancer comes from quite different situations being given the same name.
| Situation | Who it applies to | What is actually done | Where it stands |
|---|---|---|---|
| Population screening | Adults with no symptoms, no family pattern and no inherited gene change. | Nothing. No test is recommended, and none has been shown to help this group. | Not recommended by NCCN or by international consensus guidance. |
| High-risk surveillance | People with a qualifying inherited gene change, or several close relatives affected. | MRI with MRCP and endoscopic ultrasound, alternating at set intervals from a defined starting age. | Recommended for this narrow group — see who is offered high-risk screening. |
| Cyst follow-up | Anyone whose scan has already shown a pancreatic cyst, usually found by chance. | Interval MRI with MRCP, checking a defined list of features rather than simply repeating the scan. | Recommended once a cyst is known about. Most such cysts are benign. |
| Investigating a symptom | Anyone with painless jaundice, unexplained weight loss, or new upper abdominal or back pain. | Pancreatic-protocol contrast CT first, then MRI or endoscopic ultrasound where the CT leaves a question. | This is diagnosis, not screening — see how pancreatic cancer does get found early. |
| Health-package testing | Well adults buying an annual check that includes marker panels or a general scan. | Tests not designed for the pancreas, read without a clinical question behind them. | Not a substitute for any of the rows above, and not a pancreatic cancer test for healthy people. |
One thing cuts across all of this. If the whites of your eyes or your skin have turned yellow and it does not hurt, that is not something to screen for later — it needs looking at this week. Painless jaundice is far more often caused by something other than cancer, and that is exactly why it is worth settling quickly rather than dreading quietly. Book a free consultation or call 1800 202 8726.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
No Screening Test Does Not Mean Nothing Can Be Done
Knowing your own risk, and knowing what to act on, is worth more than a scan that was never built for this.
If you are well and worried
What Actually Helps, When There Is No Test to Buy
None of this is a screening test. All of it is more useful than one.
- Map your family history properly, once. Write down which relatives had which cancer, and roughly how old they were, on both sides. This one exercise is what decides whether you belong to the small group for whom surveillance is genuinely recommended, and it costs nothing.
- Learn the symptom pattern instead of buying scans. Knowing what to act on protects you more than an annual test that was never designed to find this cancer — how pancreatic cancer gets found early sets out what those signs are.
- Painless jaundice is the one same-week item. Yellow eyes or skin without pain should not wait for the next convenient appointment, whatever else is or is not being screened for.
- Stopping smoking does more than any test would. It is the largest modifiable risk factor for this cancer. No scan offers a comparable reduction in risk, and the benefit keeps building over the years after quitting.
- Take new diabetes in later life seriously when weight is falling with it. Diabetes appearing for the first time in an older adult who is losing weight without trying is worth a proper look rather than a repeat sugar test alone. New diabetes almost never means cancer — but this particular combination deserves a conversation.
- If a scan has already found a cyst, follow it up correctly. A known pancreatic cyst is followed on a defined schedule with defined checks. That is surveillance of something real, and it replaces any argument about screening.
- Do not book repeat whole-body scans “just in case.” Each one carries a radiation dose and a fair chance of turning up an unrelated finding that leads to more tests. Repeated scanning of a healthy person is not the cautious choice it feels like.
What actually happens
What Happens If You Bring This Question to Us
-
A conversation, not a scan sale
The first consultation is free and lasts 45 minutes. If you have come asking to be screened, the first job is to work out whether any test would help you at all — and to say so plainly when the answer is no.
Free 45-minute consultation at CION -
Your history is checked against the criteria
Family history on both sides, your own medical history, smoking, any previous pancreatitis, any cyst found on an earlier scan, and how your diabetes began if you have it. These are the things the published eligibility criteria are built from.
In-house at CION -
Genetic counselling where the history warrants it
If the pattern suggests an inherited predisposition, you are counselled before any gene test is sent, so you understand what a result would and would not mean for you and for your relatives.
Genetic counselling in-house at CION -
Imaging only where there is a reason to look
Where a symptom or a finding justifies it, a pancreatic-protocol contrast CT or an MRI with MRCP is ordered and reported properly, rather than a general scan read without a question behind it.
Ordered and reported in-house at CION -
Entry into a surveillance pathway if you qualify
If you meet the criteria, you go onto a defined interval schedule, with your scans compared against each other over time rather than read in isolation. That comparison is what makes a change detectable at all.
MRI in-house at CION; endoscopic ultrasound coordinated with specialist endoscopy partners
Plainly stated
What CION Delivers, and What Is Coordinated
Being clear about this at the outset saves a difficult conversation later, and it matters particularly on a page about tests, because tests are usually where the billing question first appears.
Delivered in-house at CION, across 35+ centres in Telangana and Andhra Pradesh: risk assessment and genetic counselling; the ordering and reporting of pancreatic-protocol CT, MRI with MRCP, CA 19-9 and routine bloods; medical oncology — chemotherapy before surgery, after surgery and for advanced disease, PARP-inhibitor-class maintenance where an inherited BRCA change is found, immune checkpoint inhibitor therapy where the tumour is mismatch-repair deficient, and systemic treatment for neuroendocrine tumours including somatostatin-analogue-class therapy; radiation, chemoradiation and SBRT; nutrition and pancreatic enzyme replacement; pain relief, psycho-oncology and supportive care; and survivorship follow-up.
Coordinated with specialist HPB, gastroenterology and endoscopy partner centres, and may be billed there: endoscopic ultrasound with biopsy, which is the surveillance test people most often ask us about; all pancreatic surgery, including the Whipple procedure and distal pancreatectomy; ERCP and biliary or duodenal stenting; staging laparoscopy; coeliac plexus block for pain; PET-CT and DOTATATE PET; and peptide receptor radionuclide therapy. We arrange these, we sit in on the decisions that follow, and we tell you in advance where each one happens and who invoices you. We do not describe them as our own endoscopy or theatre lists, because they are not.
If you have been told there is nothing to screen you for and that has left you feeling unprotected, bring your family history and any reports you already have. We will tell you plainly whether surveillance applies to you, and what is worth doing if it does not. See also pancreatic cancer treatment in Hyderabad, or book a free consultation or call 1800 202 8726.
Take the next step
Get the Screening Question Settled Properly
One honest conversation about your risk is worth more than a year of searching. We walk this journey with you.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
Common questions
Pancreatic cancer screening — your questions answered
Is there a blood test that can screen for pancreatic cancer?
No blood test is recommended for screening people who feel well. The marker most often asked about, CA 19-9, was developed to follow a cancer that has already been diagnosed and to see how it responds to treatment. It goes up in gallstone disease, in pancreatitis and whenever the bile duct is blocked for any reason, so a raised result in a well person far more often reflects something benign than a cancer. It can also stay inside the normal range while a tumour is present, and a proportion of people never produce it at all because of their Lewis blood-group type. A normal result is therefore not a clean bill of health, and a raised one is not a diagnosis. Neither reading tells you the thing you wanted to know.
My health package included a CA 19-9 and it came back high. What should I do?
Do not panic, and do not ignore it either. Take the result to a doctor who will read it alongside everything else rather than simply repeating it in isolation. The usual next step is a clinical assessment and, where there is any reason for concern, a dedicated pancreatic-protocol contrast CT rather than a general scan. Far more often than not the explanation turns out to be benign: gallstones, an episode of pancreatitis, a blocked bile duct, or the ordinary variation seen in people with no disease at all. A single high reading in someone with no symptoms is a reason for a proper look, not a reason to assume the worst. What is not helpful is repeating the same blood test every few weeks and watching the number move, without anyone deciding what it would actually take to settle the question.
Should I get a whole-body PET-CT scan to check for pancreatic cancer?
It was not designed for that and it is not recommended for it. PET-CT is a staging test used once a cancer has been diagnosed, to see where else it has reached. Performed on a person with no symptoms, it highlights inflammation as readily as tumour and commonly turns up unrelated findings in the thyroid, lung, bowel or elsewhere that then have to be investigated, each with its own delay, cost and anxiety. It also carries a radiation dose that is entirely reasonable when there is a clinical question and hard to justify when there is not. At CION, PET-CT is coordinated with partner imaging centres and may be billed there, and it is arranged where there is a genuine clinical reason for it rather than as a check-up.
My father had pancreatic cancer. Should I be screened?
Possibly, and this is the situation where the question is genuinely worth asking. One affected relative on its own does not usually meet the published criteria for surveillance. Several close relatives affected, a relative diagnosed unusually young, or a known inherited gene change in the family can change that answer completely. What settles it is a proper family history taken across both sides of the family, followed by genetic counselling if the pattern suggests an inherited predisposition. That assessment is available in-house at CION and commits you to nothing. If you do meet the criteria, surveillance is a defined programme with set intervals rather than an occasional scan, and our page on screening for people at high risk explains exactly what it involves and where each part of it happens.
Can an ultrasound or a routine CT scan pick up pancreatic cancer early?
Sometimes, but neither is reliable enough to be used as a screening test. An ultrasound of the upper abdomen is good at showing gallstones and a dilated bile duct, and that dilated duct is occasionally the first clue that something is obstructing it. The gland itself sits behind the stomach and behind bowel gas, and the tail is often not visible at all, so a normal ultrasound does not exclude anything. A general abdominal CT done for an unrelated reason can show a larger tumour, but a small one may only be visible on a dedicated pancreatic-protocol study timed to the arterial and venous phases of contrast. Cancers are found by chance on both of these scans. That is luck rather than screening, and it is not something to rely on.
I have just developed diabetes and I am losing weight. Should I be screened?
This particular combination deserves a proper assessment, though it still does not amount to screening. Diabetes appearing for the first time in an older adult who is also losing weight without trying, or who has new upper abdominal or back discomfort, is worth investigating rather than managing with a repeat sugar test alone. The overwhelming majority of people who develop diabetes in later life do not have pancreatic cancer, and it would be wrong to suggest otherwise. But the pancreas produces insulin, and a tumour growing in it can occasionally disturb sugar control before anything else shows. If that pattern describes you, ask for a clinical review and, where indicated, dedicated pancreatic imaging. That is investigating a finding, which is a different and far more useful thing than screening.
What does CION do for someone worried about pancreatic cancer screening, and what happens at the first visit?
The first consultation is free and lasts 45 minutes, and it is a genuine review rather than a booking appointment. We take a full family history across both sides, go through your own medical history, and check it against the published criteria that decide whether surveillance applies to you. If it does, we set up a defined interval schedule. If it does not, we say so plainly instead of ordering a scan to make the visit feel worthwhile. Risk assessment, genetic counselling and testing, and the ordering and reporting of pancreatic-protocol CT, MRI with MRCP, CA 19-9 and bloods are all in-house at CION. Endoscopic ultrasound, ERCP and stenting, PET-CT and DOTATATE PET, and all pancreatic surgery are coordinated with specialist HPB, gastroenterology and endoscopy partner centres and may be billed there. Bring whatever reports you already have.
Medical disclaimer: This page explains why no pancreatic cancer screening test is recommended for adults at average risk, what commonly requested tests actually measure, and how surveillance for high-risk individuals differs. It is reviewed by a CION medical oncologist with reference to NCCN guidance on pancreatic adenocarcinoma and to international consensus recommendations on pancreatic surveillance. It is general information and is not a substitute for individual assessment; whether any testing applies to you depends on your own family and medical history and should be discussed with your treating team. Risk assessment and genetic counselling, the ordering and reporting of pancreatic-protocol CT, MRI with MRCP, CA 19-9 and bloods, chemotherapy, radiation, chemoradiation and SBRT, nutrition and enzyme support, pain relief, psycho-oncology and survivorship care are delivered by CION; endoscopic ultrasound and biopsy, ERCP and stenting, staging laparoscopy, coeliac plexus block, PET-CT and DOTATATE PET, peptide receptor radionuclide therapy and all pancreatic surgery are coordinated with specialist HPB, gastroenterology and endoscopy partner centres and may be billed there.